Amicare Sp. z o.o. S.K.

Lodz 41 trials 17 recruiting

41 Registered trials

17 Currently recruiting

Organisation

Amicare Sp. z o.o. S.K.

Location

Lodz, Poland

Identifier

ORG-100044534

Address

Ul. Zgierska 249, 91-495, Poland

Departments

-
#40734: Neurology
Allergology
AMICARE CENTRUM MEDYCZNE
AmiCare sp. z o.o. sp. k.
Dermatology
Gastroenterology
N/A
NA
Neurology
Not Applicable
PL10011: Gastroenterologia
S.K. Amicare centrum medyczne Oddział Łódź

Clinical trials at this site (41)

Search interface

ELEVATE UC OLE: An Open-Label Extension Study for Treatment of Moderately to Severely Active Ulcerative Colitis Ended

2024-515156-21-00 Ulcerative Colitis 5 2020-01-09
A study to compare the effect of AVT16 and Entyvio® in subjects with moderate to severe active ulcerative colitis. Ended

2023-507705-34-00 Moderate to Severe Active Ulcerative Colitis 5 2025-08-29
A study to investigate the efficacy and safety of subcutaneous lunsekimig (SAR443765) compared with placebo in adult participants with moder… Ended

2024-511549-20-00 Dermatitis atopic 4 2025-04-22
A randomized, double blind, placebo-controlled, dose response, phase II, multicentre trial to evaluate the efficacy and safety of oral AP118… Ended

2024-514981-37-00 Rheumatoid Arthritis 4 2024-12-05
Evaluation of efficacy and safety of 0.1% mometasone furoate cutaneous emulsion compared to its active ingredient-free base and a comparator… Ended

2024-511583-82-00 Plaque psoriasis 5 2024-10-08
Efficacy and Safety of Rosnilimab in Subjects with Ulcerative Colitis Ended

2023-508679-34-00 Ulcerative Colitis 4 2024-07-30
A prospective, randomized, double-blind placebo-controlled multicentre study with mannan-conjugated birch pollen allergoids administered sub… Ended

2023-508013-16-00 Birch pollen induced allergic rhinitis or rhinoconjunct 5 2024-02-26
Study to Evaluate the Clinical Activity and Safety of Oral NX-13 in Participants with Moderate to Severe Ulcerative Colitis Ended

2022-503005-38-00 Ulcerative Colitis 4 2023-12-04
A Study to Investigate Bowel Urgency in Adults with Moderately to Severely Active Ulcerative Colitis Treated with Mirikizumab Ended

2022-502393-16-00 Moderately to Severely Active Ulcerative Colitis 5 2023-09-06
Basimglurant in children, adolescents, and young adults with TSC Ended

2024-512611-53-00 Tuberous Sclerosis Complex 4 2023-06-30
ABTECT-1 – ABX464 Treatment Evaluation for ulcerative Colitis Therapy -1 Ended

2022-500535-36-01 Moderately to severely active ulcerative colitis 5 2023-06-12
Phase 3, 52-week Study Evaluating Rocatinlimab (AMG451)in Adolescent Subjects With Moderate-to-severe AD (ROCKET-ASTRO) Ended

2022-501586-50-00 Atopic Dermatitis 5 2023-05-15
A Phase 3, Placebo-controlled, Double-blind Study Assessing Rocatinlimab (AMG 451) Monotherapy in Moderate-to-severe AD (ROCKET-Horizon) Ended

2022-501538-44-00 Atopic Dermatitis 5 2023-04-25
Clinical study to show if Naronapride tablets are safe and efficient for treatment of delayed stomach emptying and to find the optimal dose. Ended

2023-510195-31-00 Idiopathic or Diabetic Gastroparesis 4 2023-01-03
VTX002 versus Placebo for the Treatment of Moderately to Severely Active Ulcerative Colitis Ended

2023-509233-39-00 Moderately to Severely Active Ulcerative Colitis 4 2022-01-20
A Multicenter, Randomized, Double Blind, Parallel Group Study to Assess the Efficacy and Safety of Oral Etrasimod as Induction and Maintenan… Ended

2024-513569-38-00 Crohn's Disease 10 2021-07-09
The efficacy and the safety of two doses of CHF6001 for the treatment of Chronic Obstructive Pulmonary Disease (COPD) Ended

2023-510175-60-00 Chronic obstructive pulmonary disease (COPD) and Chron 5 2021-06-16